Immunome (NASDAQ:IMNM) Shares Down 3.3%

Immunome, Inc. (NASDAQ:IMNM) shares fell 3.3% on Tuesday . The stock traded as low as $15.11 and last traded at $15.27. 616,752 shares changed hands during trading, a decline of 20% from the average session volume of 768,748 shares. The stock had previously closed at $15.79.

Analysts Set New Price Targets

IMNM has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Tuesday, August 13th. Piper Sandler cut their price objective on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $29.00.

Immunome Price Performance

The company has a market capitalization of $923.52 million, a price-to-earnings ratio of -2.04 and a beta of 1.77. The firm’s 50-day simple moving average is $14.34 and its two-hundred day simple moving average is $16.32.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. The firm had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $2.62 million. On average, analysts expect that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Jack Higgins sold 3,524 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the sale, the insider now directly owns 16,000 shares in the company, valued at $222,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime acquired 7,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the purchase, the director now owns 16,615 shares in the company, valued at $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is owned by corporate insiders.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. Arizona State Retirement System boosted its stake in shares of Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the last quarter. Clear Creek Financial Management LLC boosted its position in Immunome by 18.2% during the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after acquiring an additional 4,035 shares during the last quarter. AQR Capital Management LLC grew its stake in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares during the period. EntryPoint Capital LLC raised its holdings in Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Immunome during the 2nd quarter worth $81,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.